To Increase Patient Access
End Brain Cancer Mobile App to download your number one tool for navigating this disease.

January 9, 2024

ONLY FOUR SPOTS LEFT! Opportunity for Patients Living with rGBM

raising voices banner 1

Online Interview for Patients & Caregivers

living with rGBM poster

Your perspectives and insights will help to shape future treatments for GBM!
Call 425.436.8688 or click below.

Read EBCI's Press Release from December 15, 2023: The End Brain Cancer Initiative (EBCI) Raising Patient Voices with a Study for Patients with Recurrent Glioblastoma (rGBM)

Understanding newly diagnosed, first recurrent, and recurrent ... in GBM

Newly Diagnosed GBM

Signifies the initial diagnosis of glioblastoma multiforme. It occurs when a patient experiences symptoms like headaches, seizures, vision problems, and seeks medical attention. During a routine check-up or through MRI and CT scans, a sizable brain mass or tumor is detected. Subsequent medical tests confirm the diagnosis of GBM.

Recurrent GBM

As its name suggests, indicates the return of the cancerous tumor. This recurrence becomes apparent through a follow-up set of MRI or CT scans. Recurrent GBM implies that, despite previous interventions such as surgery, chemotherapy, and radiation, the tumor has proven resilient and reappeared in the same area of the brain.

First Recurrent GBM

Specifies that after the initial diagnosis and the treatments administered to eliminate cancer cells, this marks the first instance of recurrence or reappearance.

This PRO rGBM survey is only for patients with first recurrent GBM.

Shreya Prakash photo

Now offering evening availability!
To better accommodate working participants and those in different time zones, our Clinical Research Coordinator/Patient Navigator is now available two evenings a week to conduct rGBM Study interviews: Tuesdays and Wednesdays from 6PM to 9PM PST.

Questions? Contact Shreya Prakash: 
425-436-8688 |

sponsor list


Enhancing patient outcomes by expanding FDA-approved treatment modalities and fueling research in the pharma/bio/life sciences, device & diagnostic industries and by closing the existing GAP from initial diagnosis to IMMEDIATE AND EXPANDED ACCESS to specialists, researchers, advanced & innovative treatments, clinical trials and critical care with the ultimate goal of improving patient outcomes through updating and improving WHO & NCCN Guidelines and clinical practices related to Standard of Care for brain cancer patients.

TAX ID:26-2185614
corporate partners
upcoming events
About us
linkedin facebook pinterest youtube rss twitter instagram facebook-blank rss-blank linkedin-blank pinterest youtube twitter instagram